Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 10, 2013, Pages 1282-1290

  Zhang, Min Yue ^a   Fung, Tsz Kin ^b   Chen, Fang Yuan ^a   Chim, Chor Sang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CISH; Methylation; MSP primer; Myeloproliferative neoplasms; SHP1; SOCS1; SOCS2; SOCS3

Indexed keywords

CYTOKINE INDUCIBLE SH2 CONTAINING PROTEIN; CYTOKINE INDUCIBLE SH2-CONTAINING PROTEIN; PRIMER DNA; PROTEIN TYROSINE PHOSPHATASE SHP 1; SUPPRESSOR OF CYTOKINE SIGNALING;

ARTICLE; CISH; GENETICS; HUMAN; METABOLISM; METHYLATION; MSP PRIMER; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASMS; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHP1; SOCS1; SOCS2; SOCS3; TUMOR CELL LINE;

CISH; METHYLATION; MSP PRIMER; MYELOPROLIFERATIVE NEOPLASMS; SHP1; SOCS1; SOCS2; SOCS3;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; METHYLATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84888388716     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12103     Document Type: Article

References (35)

1. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008; 83: 491-7.
2. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005; 165: 2651-8.
3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24: 1128-38.
4. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008; 22: 1299-307.
5. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000; 95: 19-29.
6. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109(Suppl.): S121-31.
7. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002; 2: 410-6.
8. Myers MP, Andersen JN, Cheng A, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem. 2001; 276: 47771-4.
9. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol. 2003; 4: 1169-76.
10. Lin LI, Tien HF. SOCS1 (Suppressor of cytokine signaling 1). Atlas Genet Cytogenet Oncol Haematol. 2007; Available at http://atlasgeneticsoncology.org/Genes/SOCS1ID42350ch16p13.html.
11. Fernández-Pérez L, Flores-Morales A. SOCS2 (suppressor of cytokine signaling 2). Atlas Genet Cytogenet Oncol Haematol. 2007. Available at http://atlasgeneticsoncology.org//Genes/SOCS2ID44123ch12q21.html.
12. Culig Z. SOCS3 (suppressor of cytokine signaling 3). Atlas Genet Cytogenet Oncol Haematol. 2012. Available at http://atlasgeneticsoncology.org//Genes/SOCS3ID44124ch17q25.html.
13. Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH roadmap epigenomics mapping consortium. Nat Biotechnol. 2010; 28: 1045-8.
14. Wu C, Sun M, Liu L, et al. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003; 306: 1-12.
15. Wang LQ, Liang R, Chim CS. Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. Expert Rev Mol Diagn. 2012; 12: 755-65.
16. Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012; 33: 1629-38.
17. Yim RL, Kwong YL, Wong KY, et al. DNA methylation of tumor suppressive miRNAs in non-Hodgkin's lymphomas. Front Genet. 2012; 3: 233.
18. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol. 2002; 20: 167-76.
19. Barrio S, Gallardo M, Albizua E, et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J Clin Pathol. 2011; 64: 1010-3.
20. Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2008; 141: 504-11.
21. Fernández-Mercado M, Cebrián V, Euba B, et al. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leuk Res. 2008; 32: 1638-40.
22. Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008; 93: 1635-44.
23. Jost E, do O N, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007; 21: 505-10.
24. Chim CS, Fung TK, Cheung WC, et al. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004; 103: 4630-5.
25. Chim CS, Kwong YL. How frequent is SOCS1 methylation in acute myeloid leukaemia? Br J Haematol. 2004; 127: 609-11.
26. Chim CS, Fung TK, Liang R. Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia. J Clin Pathol. 2010; 3: 518-21.
27. Chim CS, Wan TS, Fung TK, et al. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol. 2010; 63: 942-6.
28. Chim CS, Wan TS, Wong KY, et al. vMethylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med. 2011; 9: 197.
29. Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008; 123: 1586-92.
30. Quentmeier H, Geffers R, Jost E, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 2008; 22: 2169-75.
31. He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 2003; 100: 14133-8.
32. Watanabe D, Ezoe S, Fujimoto M, et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol. 2004; 126: 726-35.
33. Nagai H, Naka T, Terada Y, et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet. 2003; 48: 65-9.
34. Födermayr M, Zach O, Huber M, et al. The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential thrombocythemia. Leuk Res. 2012; 36: 588-90.
35. Melki JR, Vincent PC, Clark SJ. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia. 1999; 13: 877-83.